FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008049114> ?p ?o ?g. }

• W2008049114 endingPage "480" @default.
• W2008049114 startingPage "472" @default.
• W2008049114 abstract "Abstract. Jönsson B, Hansson L, Stålhammar N‐O (Stockholm School of Economics, Stockholm; University of Uppsala, Uppsala, Sweden; and AstraZeneca Pharmaceuticals, DE, USA). Health economics in the Hypertension Optimal Treatment (HOT) study costs and cost‐effectiveness of intensive blood pressure lowering and low‐dose aspirin in patients with hypertension. J Intern Med 2003; 253: 472–480. Objectives. To investigate the marginal cost‐effectiveness of different targets for the reduction of blood pressure and the cost‐effectiveness of adding acetylsalicylic acid (ASA) to the treatment of hypertension. Design. Patients with hypertension were randomized to three target groups for blood pressure; ≤90, ≤85 and ≤80 mmHg. Patients were also randomly assigned ASA and placebo. The average follow‐up time was 3.8 years. The direct costs for drugs, visits, hospitalizations, and side‐effects were calculated and related to clinical outcome. Setting. Resource utilization data from all the 26 countries in the study were pooled, and Swedish unit costs were applied to the aggregated resource utilization. Subjects. A total of 18 790 patients, 50–80 years of age (mean 61.5 years), with a diastolic blood pressure between 100 and 115 mmHg (mean 105 mmHg). Interventions. Antihypertensive treatment with the long‐acting calcium antagonist felodipine was given to all patients. Additional therapy and dose increments in four further steps were prescribed to reach the randomized target blood pressure. Fifty per cent of the patients were randomized to a low dose, 75 mg daily, of acetylsalicylic acid. Main outcome measures. Direct health care costs, major cardiovascular (CV) events (myocardial infarction and stroke) and CV death. Results. The average cost of drugs and visits increased with more intensive treatment. The increase in treatment costs was partly but not fully offset by a nonsignificant reduction in the cost of CV hospitalizations. For patients with diabetes there were no significant differences in total cost between the target groups. The cost of avoiding a major CV event was negative in the base case analysis, SEK −10 360 (CI: −78 195, 75 630), and SEK 18 450 (CI: −88 789, 192 980) in a sensitivity analysis. For patients on ASA, costs were slightly but significantly higher than for patients on placebo. The estimates of the cost of avoiding a major CV event varied between SEK 41 600 and SEK 477 400, with very wide confidence intervals. Conclusions. The treatment cost increases as the target for hypertension treatment is lowered. In patients with diabetes, intensive treatment to a lower target is cost‐effective. Because of the nonsignificant difference in events, no conclusion can be made for all patients in the study. Furthermore, no conclusive evidence was found regarding the cost‐effectiveness of adding ASA to the treatment of hypertension." @default.
• W2008049114 created "2016-06-24" @default.
• W2008049114 creator A5012412741 @default.
• W2008049114 creator A5045736313 @default.
• W2008049114 creator A5056780597 @default.
• W2008049114 date "2003-03-21" @default.
• W2008049114 modified "2023-10-15" @default.
• W2008049114 title "Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension" @default.
• W2008049114 cites W1971791904 @default.
• W2008049114 cites W2000009266 @default.
• W2008049114 cites W2055080961 @default.
• W2008049114 cites W2109592076 @default.
• W2008049114 cites W2137408480 @default.
• W2008049114 cites W2162962682 @default.
• W2008049114 cites W2166033530 @default.
• W2008049114 cites W2183761985 @default.
• W2008049114 cites W4246362004 @default.
• W2008049114 cites W2118282635 @default.
• W2008049114 doi "https://doi.org/10.1046/j.1365-2796.2003.01135.x" @default.
• W2008049114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12653877" @default.
• W2008049114 hasPublicationYear "2003" @default.
• W2008049114 type Work @default.
• W2008049114 sameAs 2008049114 @default.
• W2008049114 citedByCount "37" @default.
• W2008049114 countsByYear W20080491142012 @default.
• W2008049114 countsByYear W20080491142014 @default.
• W2008049114 countsByYear W20080491142015 @default.
• W2008049114 countsByYear W20080491142016 @default.
• W2008049114 countsByYear W20080491142019 @default.
• W2008049114 countsByYear W20080491142020 @default.
• W2008049114 countsByYear W20080491142022 @default.
• W2008049114 crossrefType "journal-article" @default.
• W2008049114 hasAuthorship W2008049114A5012412741 @default.
• W2008049114 hasAuthorship W2008049114A5045736313 @default.
• W2008049114 hasAuthorship W2008049114A5056780597 @default.
• W2008049114 hasConcept C112930515 @default.
• W2008049114 hasConcept C118190526 @default.
• W2008049114 hasConcept C126322002 @default.
• W2008049114 hasConcept C142724271 @default.
• W2008049114 hasConcept C168563851 @default.
• W2008049114 hasConcept C194828623 @default.
• W2008049114 hasConcept C204787440 @default.
• W2008049114 hasConcept C27081682 @default.
• W2008049114 hasConcept C2777628954 @default.
• W2008049114 hasConcept C2780648877 @default.
• W2008049114 hasConcept C3019080777 @default.
• W2008049114 hasConcept C71924100 @default.
• W2008049114 hasConcept C84393581 @default.
• W2008049114 hasConceptScore W2008049114C112930515 @default.
• W2008049114 hasConceptScore W2008049114C118190526 @default.
• W2008049114 hasConceptScore W2008049114C126322002 @default.
• W2008049114 hasConceptScore W2008049114C142724271 @default.
• W2008049114 hasConceptScore W2008049114C168563851 @default.
• W2008049114 hasConceptScore W2008049114C194828623 @default.
• W2008049114 hasConceptScore W2008049114C204787440 @default.
• W2008049114 hasConceptScore W2008049114C27081682 @default.
• W2008049114 hasConceptScore W2008049114C2777628954 @default.
• W2008049114 hasConceptScore W2008049114C2780648877 @default.
• W2008049114 hasConceptScore W2008049114C3019080777 @default.
• W2008049114 hasConceptScore W2008049114C71924100 @default.
• W2008049114 hasConceptScore W2008049114C84393581 @default.
• W2008049114 hasIssue "4" @default.
• W2008049114 hasLocation W20080491141 @default.
• W2008049114 hasLocation W20080491142 @default.
• W2008049114 hasOpenAccess W2008049114 @default.
• W2008049114 hasPrimaryLocation W20080491141 @default.
• W2008049114 hasRelatedWork W1983211022 @default.
• W2008049114 hasRelatedWork W1991628673 @default.
• W2008049114 hasRelatedWork W2029345299 @default.
• W2008049114 hasRelatedWork W2032633698 @default.
• W2008049114 hasRelatedWork W2034497865 @default.
• W2008049114 hasRelatedWork W2054543578 @default.
• W2008049114 hasRelatedWork W2090028217 @default.
• W2008049114 hasRelatedWork W2373391054 @default.
• W2008049114 hasRelatedWork W2375776082 @default.
• W2008049114 hasRelatedWork W2953368497 @default.
• W2008049114 hasVolume "253" @default.
• W2008049114 isParatext "false" @default.
• W2008049114 isRetracted "false" @default.
• W2008049114 magId "2008049114" @default.
• W2008049114 workType "article" @default.